Loading...
XSHG
600062
Market cap2.52bUSD
Jul 09, Last price  
16.43CNY
1D
-0.90%
1Q
-10.02%
Jan 2017
6.41%
Name

China Resources Dubl-Crne Phrmctl Co Ltd

Chart & Performance

D1W1MN
XSHG:600062 chart
P/E
10.36
P/S
1.55
EPS
1.59
Div Yield, %
2.87%
Shrs. gr., 5y
-0.18%
Rev. gr., 5y
5.28%
Revenues
11.00b
-1.88%
4,049,090,0234,556,616,3814,951,524,3675,037,946,4175,366,795,8116,337,323,5076,989,323,4076,834,574,3255,153,228,9225,138,395,4015,494,803,8686,421,846,7688,225,083,3129,380,989,9268,503,938,2289,111,516,9309,625,315,86711,310,143,63911,211,623,66511,000,795,324
Net income
1.65b
+1.18%
164,893,391437,580,763380,572,486454,017,996520,094,650528,998,582614,408,189870,690,223736,623,977661,063,525714,210,867842,612,502968,593,3941,055,123,7141,005,161,642935,685,4881,180,062,4181,670,383,4121,627,718,4101,646,949,551
CFO
1.49b
-18.39%
303,708,790235,458,162331,710,145342,013,845509,674,695511,526,104396,048,302546,240,145718,376,437701,346,759771,247,8221,187,087,9901,469,039,6311,439,788,4701,360,158,2101,340,920,9631,341,669,6481,650,775,9921,825,115,1911,489,514,452
Dividend
Oct 28, 20250.1 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
IPO date
May 22, 1997
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT